B+
Bull case
20%
Probability
Target price
$12.00
+176.5% vs current
Cautiously constructive: a few analyst upgrades and $12 highs lift upside interest, but coverage is mixed and sentiment remains event-driven pending earnings and execution.
No evidence quality warning is currently attached to this memo.
Broker upgrades and target revisions (e.g., recent $12 raise) may drive short-term re‑rating; timing is estimated as quarter-end effect.
Quarterly results and management guidance that can re-price estimates; recent analyst activity increases sensitivity to the release.
Broader physician adoption, expanded channels, or reimbursement wins that materially grow procedure volume and margins over 12+ months.
No formal recommendation provided.